Eltrombopag (Revolade) is an oral thrombopoietin receptor agonist that plays an important role in the treatment of various hematological diseases.

How Effective Is Eltrombopag (Revolade) in Treatment?

Efficacy in Chronic Immune Thrombocytopenia (ITP)

Eltrombopag can significantly increase the platelet count in patients with chronic ITP and reduce the risk of bleeding.

Clinical studies have shown that this drug can maintain platelets at a safe level and reduce the occurrence of bleeding events.

Efficacy in Chronic Hepatitis C-Associated Thrombocytopenia

For patients with chronic hepatitis C who need to receive interferon treatment, eltrombopag can effectively correct thrombocytopenia, enabling patients to initiate and maintain antiviral therapy.

Suitable Populations for Eltrombopag (Revolade)

Patients with Chronic ITP

Suitable for children aged 1 year and older and adults with chronic ITP who have an inadequate response to corticosteroids, immunoglobulins, or splenectomy.

Particularly suitable for patients whose degree of thrombocytopenia and clinical status increase the risk of bleeding.

Patients with Chronic Hepatitis C

Suitable for patients with chronic hepatitis C who cannot initiate or maintain interferon treatment due to thrombocytopenia.

Patients with Severe Aplastic Anemia

Suitable for patients with severe aplastic anemia who have an inadequate response to immunosuppressive therapy.

For East Asian patients or those with liver damage, the initial dose needs to be adjusted.

Medication for Special Populations

For pregnant women, the pros and cons of medication must be weighed; lactating women should decide to discontinue the medication or stop breastfeeding.

Elderly patients do not need dose adjustment, but close monitoring is required.

Patients with hepatic impairment need to use the medication at a reduced dose, while patients with renal impairment do not need dose adjustment.

East Asian patients also need dose adjustment due to metabolic differences.

Medication Monitoring for Eltrombopag (Revolade)

Pre-Treatment Assessment

Conduct a comprehensive assessment of liver function (ALT, AST, bilirubin).

Perform a baseline ophthalmic examination (to assess the risk of cataracts).

Collect a detailed medication history (with special attention to drugs containing polyvalent cations).

Hematological Monitoring

For ITP patients: Monitor platelets weekly initially, and once a month after stabilization.

For hepatitis C patients: Monitor platelets weekly during antiviral treatment.

For aplastic anemia patients: Regularly assess the complete blood cell count (three lineages).

Liver Function Monitoring

Monitor liver function every 2 weeks during the dose adjustment period.

Monitor liver function once a month after reaching a stable dose.

If abnormal liver enzymes occur, the frequency of monitoring needs to be increased.